We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

59 hedge funds and large institutions have $225M invested in VanEck Pharmaceutical ETF in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more capital invested

Capital invested by funds: $157M → $225M (+$68.1M)

20.11% more ownership

Funds ownership: 49.03% → 69.14% (+20%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less funds holding

Funds holding: 60 → 59 (-1)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

26% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 19

Holders
59
Holders Change
-1
Holders Change %
-1.67%
% of All Funds
1.55%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
14
Reduced
19
Closed
7
Calls
$261K
Puts
–
Net Calls
+$261K
Net Calls Change
-$476K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$23.2M
2
Bank of America
Bank of America
North Carolina
+$2.78M
3
LPL Financial
LPL Financial
California
+$927K
4
M&T Bank
M&T Bank
New York
+$875K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$537K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$5.59M
2
CS
Credit Suisse
Switzerland
-$4.68M
3
MIM
Macroview Investment Management
Maryland
-$2.84M
4
Jane Street
Jane Street
New York
-$2.45M
5
VF
Virtu Financial
New York
-$2.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
NAM
26
NTV Asset Management
West Virginia
$388K – – –
CCT
27
Country Club Trust
Missouri
$356K +$2.58K +40 +0.7%
FPCM
28
Financial Partners Capital Management
New York
$345K -$12.9K -200 -4%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$327K -$4.2K -65 -1%
Wells Fargo
30
Wells Fargo
California
$327K – – –
JWM
31
Jacobus Wealth Management
Wisconsin
$311K – – –
VFS
32
VSR Financial Services
Kansas
$294K -$1.42K -22 -0.5%
CS
33
Credit Suisse
Switzerland
$284K -$4.68M -72,460 -94%
Ameriprise
34
Ameriprise
Minnesota
$263K +$261K +4,034 New
FMW
35
Farr Miller & Washington
District of Columbia
$261K – – –
BCM
36
Beck Capital Management
Texas
$257K +$254K +3,931 New
KFC
37
Klingenstein Fields & Co
New York
$248K – – –
HighTower Advisors
38
HighTower Advisors
Illinois
$232K +$19.4K +300 +9%
BHB
39
Bank Hapoalim BM
Israel
$228K – – –
Creative Planning
40
Creative Planning
Kansas
$225K -$236K -3,654 -51%
Bank of Montreal
41
Bank of Montreal
Ontario, Canada
$219K -$84K -1,300 -28%
JP Morgan Chase
42
JP Morgan Chase
New York
$206K -$79.7K -1,234 -28%
MA
43
MUFG Americas
New York
$154K – – –
LTFS
44
Ladenburg Thalmann Financial Services
Florida
$142K – – –
HCM
45
Highlander Capital Management
New Jersey
$140K +$12.9K +200 +10%
PNC Financial Services Group
46
PNC Financial Services Group
Pennsylvania
$135K – – –
SG Americas Securities
47
SG Americas Securities
New York
$113K – – –
TCM
48
Tradewinds Capital Management
Washington
$78K – – –
GT
49
Glenmede Trust
Pennsylvania
$65K – – –
WIC
50
Woodmont Investment Counsel
Tennessee
$65K – – –
1
2
3

PPH Hedge Fund Activity: Q4 2015 in Review

59 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2015, worth a combined $225M — up 43% from $157M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of PPH and 6 opened new positions — a net loss of 1 holder — while 19 trimmed existing stakes and 14 added.

The largest buyer was Goldman Sachs, adding an estimated $23.2M. The largest seller was Morgan Stanley, cutting an estimated $5.59M.

  • 59 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2015, down from 60 in Q3 2015.
  • Funds reported $225M of VanEck Pharmaceutical ETF stock for Q4 2015, up 43% quarter-over-quarter.
  • 6 funds opened new VanEck Pharmaceutical ETF positions in Q4 2015 and 7 closed out, a net change of -1 holder.
  • The largest VanEck Pharmaceutical ETF buyer in Q4 2015 was Goldman Sachs, an estimated $23.2M added.
  • The largest VanEck Pharmaceutical ETF seller in Q4 2015 was Morgan Stanley, an estimated $5.59M sold.

Based on aggregated 13F filings for Q4 2015.